Granted Patent
B2
US 7,829,529 · App. 12/178,126 · Granted Nov 9, 2010
Use of factor VIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
Assignee:
Novo Nordisk Health Care A/G
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to cell migration or treated by specific regulation of cell migration or chemotaxis.
Claims (3)
1. A method of treating burns in a patient comprising delivering about 500 units per kg body weight/day to about 15,000 units per kg body weight/day of a purified FVIIa to the patient.
2. The method of claim 1 , wherein the purified FVIIa is recombinant FVIIa.
3. The method of claim 2 , wherein the amount of recombinant FVIIa administered to the patient is in the range of 15 μg/kg/day to 200 μg/kg/day.
Assignments (1)
CHANGE OF ADDRESS
Recorded Jun 19, 2013
From: NOVO NORDISK HEALTHCARE A/G
To: NOVO NORDISK HEALTHCARE AG
Reel/Frame 030653/0226 →
Priority Claims (2)
DK 1999 01023
· Jul 14, 1999
· national
DK 1999 01117
· Aug 12, 1999
· national
Continuity (5)
Continuation
PCTDK000040100
· Jul 14, 2000
Provisional Application
6014830000
· Aug 11, 1999